Study of efficacy and safety of secukinumab in pediatric patients with severe plaque psoriasis
- Conditions
- Severe Chronic Pediatric Plaque Psoriasis
- Registration Number
- jRCT2080223229
- Lead Sponsor
- Novartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 5
*PASI score of 20 or greater at the time of randomization (Wash-out: Other systemic immunomodulating treatments: 4weeks, Phototherapy: 2weeks, Biological immunomodulating agents: 12weeks)
*Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate) at randomization *Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Randomized, Parallel Assignment, Double Blind Study
- Primary Outcome Measures
Name Time Method - efficacy
PASI 75 and IGA 0/1
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
United States/United Kingdom/Belgium/Colombia/Egypt/Estonia/France/Germany/Guatemala/Hungary/Israel/Italy/Latvia/Poland/Rumania/Russia/Spain/Switzerland
Location not specified
United States/United Kingdom/Belgium/Colombia/Egypt/Estonia/France/Germany/Guatemala/Hungary/Israel/Italy/Latvia/Poland/Rumania/Russia/Spain/Switzerland